Latest ACE inhibitors Stories
- New data from PARADIGM-HF shows LCZ696 cut incidence of sudden deaths, emergency room visits, hospitalizations, worsening symptoms and need for more intense treatment in HFrEF patients versus enalapril(1,2) EAST
A recent breakthrough in clinical results with an experimental drug to treat heart failure has shown very promising results.
Dr. Milton Packer and Dr. McMurray will be presenting these results for the first time in the United States at the HFSA Annual Meeting LAS VEGAS, Sept.
DENVER, Sept. 8, 2014 /PRNewswire/ -- Silvergate Pharmaceuticals, Inc.
-- LCZ696 mortality benefit exceeded what was achieved with enalapril, an ACE-inhibitor, when replacing enalapril combined with current treatment
- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1) EAST HANOVER, N.J., Aug.
-- LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF EAST HANOVER, N.J., Aug.
Reportbuyer.com just published a new market research report:
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.